Hims & Hers stock tumbled after the company confirmed it would stop selling some compounded weight-loss drugs.
Hims shares have roughly doubled since the start of the year, despite the FDA’s announcement last week that Novo Nordisk’s ...
Telehealth and wellness platform Hims & Hers on Monday offered a revenue outlook for the year ahead that topped Wall Street’s ...
Hims & Hers Health reported fourth-quarter results on Monday that beat analysts’ expectations, but the stock sank in extended ...
Hims & Hers Health reported fourth-quarter revenue of $481.14 million, beating estimates of $470.31 million, according to ...
Hims & Hers projects $725M in GLP-1 weight loss revenue for 2025, a 3.2x increase from 2024. Read why I upgrade HIMS stock ...
Raising its price target on the shares to $21, reports The Fly, BofA nonetheless reiterated an "underperform" ( i.e., sell) ...
Super Micro has until Tuesday to file delayed financial accounts or risk being delisted by the Nasdaq stock exchange, Home ...
Hims & Hers reported a double beat in Q4, but faced an 18% stock drop after hours. Read why this drop is a good opportunity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback